Dentroid raises $32M Series A at $265M valuation for needle-free dental tech
What's the deal? Dentroid Technologies, a Canberra-based medtech startup, has raised $32 million in a Series A round at a $265 million valuation. The company is developing light-based technology that aims to eliminate the need for needles during dental procedures.
The round included participation from French dental products manufacturer SeptodontDealroom has a profile for this one. Try Dealroom → and former WiseTech Global director Michael Gregg. Alongside the raise, Dentroid signed a global licensing deal with Septodont to commercialise its flagship Nuralyte device.
Founded in 2017 by dentist-turned-chief executive Omar Zuaiter and robotics engineer Alaa Habeb, Dentroid has spent nine years developing Nuralyte — a device that uses pulses of light to induce pain relief in teeth and gums, reducing or removing the need for anaesthetic injections in some treatments.
Why now? The technology has completed stage one and stage two clinical trials through partnerships with the University of Maryland, the University of Queensland, Griffith University, and the University of Sydney. That clinical progress likely made the company ready for a larger raise and a global commercialisation partner.
Zuaiter told the Australian Financial Review that Australian VC investors were reluctant to back the company in its early years, citing limited appetite for medtech businesses with long development timelines. "By definition, it takes 10 to 15 years for the technologies to be developed and validated," he said.
What could go wrong? Medtech startups face a long road from clinical trials to regulatory approval and mass adoption. Even with a strategic partner like Septodont, Dentroid must still prove that its light-based approach works reliably enough to replace a well-established standard of care.
Dentist and patient adoption is another hurdle. Any new device must clear not just regulatory bars but also the practical scepticism of practitioners who have relied on injections for decades.
The signal: Dentroid's $32 million Series A, backed by a corporate investor rather than traditional VCs, underscores a persistent gap in Australia's early-stage funding landscape for medtech companies with long development cycles. Septodont's dual role as both a corporate investor and global licensing partner suggests that for capital-intensive deep-tech startups, strategic industry backers — not generalist VC firms — may offer the most viable path from clinical validation to commercialisation.
Read more: SmartCompany
